Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a dual DNA-RNA approach unlock Parkinson's genetic secrets?

NCT ID NCT06576713

Diagnosis Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study aims to find the missing genetic causes of Parkinson's disease in people with early-onset or familial forms who haven't received a molecular diagnosis. Researchers will use a combination of whole genome and RNA sequencing to look for hidden genetic variants. The goal is to improve genetic counseling and potentially identify new therapeutic targets.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Combined whole genome and RNA sequencing
What this could lead to
If successful, this could identify new genetic causes of Parkinson's, enabling better genetic counseling, earlier diagnosis, and potential targets for future treatments.
What could go wrong
This is a small, early-stage study with only 14 participants, so findings may not apply broadly. The technology is complex, and not all genetic causes may be found.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Extrapyramidal syndrome beginning before or at the age of 40 or associated with a family history: * Dopaminergic denervation proven by ioflupane brain scintigraphy (DaTscan®) * DNAs from both asymptomatic parents available in biobank * Subject affiliated to a social protection health insurance scheme or beneficiary or beneficiary * Subject able to understand the objectives and risks related to the research and to give dated and signed informed consent Exclusion Criteria: * \- Contraindication for performing a superficial skin biopsy provided for by the protocol * Molecular cause of parkinsonism previously identified * Absence of prior genetic exploration by high-throughput DNA sequencing * Patient with late-onset sporadic parkinsonian syndrome (\> 40 years) without family history * Patient with Parkinson's syndrome associated with a specific diagnosis (genetic or non-genetic pathology: exposure to neuroleptics, toxic origin) * Impossibility of providing the subject with informed information * Subject under judicial protection * Subject under guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early-onset parkinsonism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease young-onset Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, Grand Est, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.